PT  - JOURNAL ARTICLE
AU  - Lançon, Allan
AU  - Hanet, Nathalie
AU  - Jannin, Brigitte
AU  - Delmas, Dominique
AU  - Heydel, Jean-Marie
AU  - Lizard, Gérard
AU  - Chagnon, Marie-Christine
AU  - Artur, Yves
AU  - Latruffe, Norbert
TI  - Resveratrol in Human Hepatoma HepG2 Cells: Metabolism and Inducibility of Detoxifying Enzymes
AID  - 10.1124/dmd.106.013664
DP  - 2007 May 01
TA  - Drug Metabolism and Disposition
PG  - 699--703
VI  - 35
IP  - 5
4099  - http://dmd.aspetjournals.org/content/35/5/699.short
4100  - http://dmd.aspetjournals.org/content/35/5/699.full
SO  - Drug Metab Dispos2007 May 01; 35
AB  - trans-Resveratrol is a polyphenol present in several plant species. Its chemopreventive properties against several diseases have been largely documented. To validate a model for the study of the factors influencing its biological fate at the hepatic level, the metabolism and the efflux of resveratrol were studied in the human hepatoblastoma cell line, HepG2. Comparative high-performance liquid chromatography analysis of cell culture media before and after deconjugation showed that resveratrol was rapidly conjugated; at the concentration of 10 μM, it was entirely metabolized at 8 h of incubation. Two main resveratrol metabolites, monosulfate and disulfate, were identified by atmospheric pressure chemical ionization-mass spectrometry, thanks to their quasi-molecular ion and their characteristic fragmentation. To correlate with the auto-induction of resveratrol metabolism evidenced in HepG2 cells after a pretreatment for 48 h with 10 μM resveratrol, the inducibility of phase II enzymes by resveratrol was studied by real-time quantitative reverse transcriptase-polymerase chain reaction and flow cytometry. Observed, in particular, were an increase in mRNA expression levels of three metabolizing enzymes, two isoforms of UDP-glucuronosyltransferases, UGT1A1 and UGT2B7 (5-fold increased), and a sulfotransferase, ST1E1, in cells pretreated for 24 h with 10 μM resveratrol. These results were correlated with an increase in protein expression, especially after 48 h of treatment. On the other hand, the intracellular resveratrol retention in cells treated with MK571 (3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methylsulfanyl] propionic acid), a multidrug resistance-associated protein inhibitor, strongly suggests the involvement of this ABC transporter family in the efflux of resveratrol conjugates from human liver. The American Society for Pharmacology and Experimental Therapeutics